A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.

Docetaxel area under the curve (AUC 0-∞ ) was numerically higher for patients who received docetaxel-sunitinib vs those with docetaxel alone (6.48 ± 4.43 h*μg/ml vs 4.85 ± 1.76 h*μg/ml, p = 0.053), although the difference did not reach statistical significance.

also in 111,027 other papers